May 23, 2017 Oncolytics Biotech® Inc. Announces Participation in World Immunotherapy Congress USA 2017
May 17, 2017 Oncolytics Biotech® Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers
May 8, 2017 Oncolytics Biotech® Inc. Announces FDA Fast Track Designation for REOLYSIN® in Metastatic Breast Cancer
May 4, 2017 Oncolytics Biotech® Inc. Announces Voting Results from its Annual Meeting of Shareholders
Apr 26, 2017 Oncolytics Biotech® Inc. to Present at the Sixth Annual Bloom Burton & Co. Healthcare Investor Conference
Apr 5, 2017 Oncolytics Biotech® Inc.'s REOLYSIN® More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer
Mar 31, 2017 Oncolytics Biotech® Inc.'s REOLYSIN® Provides Statistically Significant Improvement in Overall Survival in Canadian Cancer Trials Group Sponsored Randomized Phase 2 Study in Metastatic Breast Cancer
